Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by BlueJays9293on May 21, 2024 2:50pm
91 Views
Post# 36050515

RE:RE:Updated prezzie

RE:RE:Updated prezzie January 2023, Baxter first announces the spinoff of it's kidney care division.  Private equity shows zero interest for all of 2023.

January 2024, Spectral begins to dramatically increase the pace of enrollment of the Tigris trial.

February 15th 2024, Spectral reaches 90 patient milestone.

March 4th 2024, Baxter discloses in a filing with the SEC, that it is in discussions with Private Equity for a possible sale of Vantive. 


<< Previous
Bullboard Posts
Next >>